Galectin Therapeutics Inc. (GALT)

[jmh0602]

I've been looking at other companies working on galectin inhibitors to compare to GALTs progress. Galecto Biotech was the private company BMY bought in 2014 for what could amount to $444 million. Their drug, TD139 just wrapped up a Phase I/Phase II study in December for the treatment of idiopathic pulmonary fibrosis through an inhaler, but I don't think any results have been posted.

Only other company with galectin inhibors mentioned is GlycoMimetics, but I don't think they even have a drug and are still working on design.
GALT seems to be the only company with a galectin inhibitor in multiple clinical studies at this time. Could GR-MD-02 be the first galectin inhibitor to market for the treatment of multiple indications? cancer, psoriasis, NASH.

Feb 7 could be a major catalyst.